chevron_leftBack
As of 24 June 2026, vTv Therapeutics Inc. has a market cap of $139.14M USD, ranking #23329 globally and #3713 in the United States.
It ranks #2096 in the Healthcare sector, and #757 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$139.14MUSD
Enterprise Value
$287.45MUSD
EBITDA (TTM)
-$32.79MUSD
Net Income (TTM)
-$26.97MUSD
PB Ratio
6.2
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Paul Sekhri
open_in_new
Employees
26
Founded
2015
IPO
30 Jul 2015
Website
vtvtherapeutics.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -2.2% | -23% | -19% | -8.2% | 50% | 35% |
News
Loading...
VTVT Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
VTVT
vTv Therapeutics Inc Class A
ISIN: US9183852048
Shares Out.:
Shares Outstanding:
3.939M1
Shares Float:
2.044M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
31.26 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About vTv Therapeutics Inc.
vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd. to develop and commercialize phosphodiesterase type 4 inhibitors program. vTv Therapeutics Inc. was incorporated in 2015 and is headquartered in High Point, North Carolina.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
547K%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
393K%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
259K%
|
97.4
|
|
NYSE: MRK
|
$274.03B
197K%
|
15.1
|
|
NYSE: PFE
|
$149.38B
107K%
|
19.5
|
|
NYSE: BMY
|
$117.58B
84K%
|
16.8
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
SIX: RO
|
$316.71B
228K%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$285.49B
205K%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$270.54B
194K%
218.9B CHF
|
20.5
|
|
CPH: NOVO-B
|
$179.71B
129K%
1.18T DKK
|
11.5
|
|
EPA: SAN
|
$108.83B
78K%
95.26B EUR
|
19.9
|
|
LSE: GSK
|
$107.21B
77K%
80.96B GBP
|
14.6
|
chevron_leftBack